Compare OTLY & ALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OTLY | ALT |
|---|---|---|
| Founded | 1994 | 1997 |
| Country | Sweden | United States |
| Employees | N/A | N/A |
| Industry | Packaged Foods | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 393.4M | 421.5M |
| IPO Year | 2021 | 2005 |
| Metric | OTLY | ALT |
|---|---|---|
| Price | $10.28 | $3.07 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 6 |
| Target Price | $14.50 | ★ $17.67 |
| AVG Volume (30 Days) | 59.3K | ★ 4.9M |
| Earning Date | 04-29-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 25.37 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $41,000.00 |
| Revenue This Year | $7.91 | N/A |
| Revenue Next Year | $5.50 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 105.00 |
| 52 Week Low | $9.40 | $2.56 |
| 52 Week High | $18.84 | $7.73 |
| Indicator | OTLY | ALT |
|---|---|---|
| Relative Strength Index (RSI) | 35.32 | 47.28 |
| Support Level | $9.79 | $2.87 |
| Resistance Level | $12.58 | $4.23 |
| Average True Range (ATR) | 0.53 | 0.18 |
| MACD | -0.26 | 0.04 |
| Stochastic Oscillator | 1.35 | 53.68 |
Oatly Group AB produces and distributes oat-based food and beverage products. Its offerings include milk, cooking creams, spreads, and yogurts. The company's products are sold through retail stores, coffee shops, and restaurants across multiple countries. It generates revenue from sales of oatmilk and other oat-based products. The company's geographical segments include Europe & International, North America and Greater China. The Europe & International segment is its maximum revenue-producing segment, followed by the North America and Greater China segments.
Altimmune Inc is a late clinical-stage biopharmaceutical company developing therapies for patients with serious liver diseases. The Company's key candidate, pemvidutide, is a dual-action therapy targeting both glucagon and GLP-1 receptors in a balanced 1:1 ratio in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD), and alcohol-associated liver disease (ALD). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.